This is a third-party research done by a grant from YuFoundation for Tom Seyfried to research Dr. Young Ko’s 3 Bromopyruvate antimetabolic drug used in cancers. The important outcome is when 3 BP was injected into the primary cancer site, the metastatic rate was impressively low. Therefore, spread of the cancers may be hindered with this molecule. Please read more in section under grants and scientific information.
Therapeutic efficacy of 3-bromopyruvate when Injected intratumorally on the growth of VM-M3 and CT-2A brain tumor cells
Thomas N. Seyfried
April 24, 2017
- The greater dependence of the VM-M3 tumor on glutaminolysis than on glycolysis for energy production.
- The low bioavailability of 3-BP after IP injection.
The glycolytic phenotype of the CT-2A glioma tumor makes this an attractive tumor model for studying 3-BP. Also, we will inject 3-BP directly into the VM-M3 and CT-2A tumors grown subcutaneously in flank.